Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Semba, T.
Right arrow Articles by Wakabayashi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Semba, T.
Right arrow Articles by Wakabayashi, T.
Clinical Cancer Research Vol. 10, 1430-1438, February 2004
© 2004 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

An Angiogenesis Inhibitor E7820 Shows Broad-Spectrum Tumor Growth Inhibition in a Xenograft Model

Possible Value of Integrin {alpha}2 on Platelets as a Biological Marker

Taro Semba, Yasuhiro Funahashi, Naoto Ono, Yuji Yamamoto, Naoko Hata Sugi, Makoto Asada, Kentaro Yoshimatsu and Toshiaki Wakabayashi

Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
We reported previously that an angiogenesis inhibitor, E7820, inhibits in vitro tube formation of human umbilical vein endothelial cell through the suppression of integrin {alpha}2 expression. Here we describe the antiangiogenic and antitumor effects of E7820 in mice and discuss the feasibility of using platelet integrin {alpha}2 expression on platelets as a biological marker of the efficacy of E7820. Oral administration of E7820 significantly inhibited basic fibroblast growth factor-induced angiogenesis in Matrigel implants and human colon WiDr tumor-induced angiogenesis in a dorsal air sac model. Twice-daily treatment with E7820 clearly inhibited the s.c. tumor growth of seven tumor cell lines derived from human colon, breast, pancreas, and kidney, and completely suppressed the growth of human pancreatic KP-1 and human colon LoVo cell lines. Moreover, E7820 significantly inhibited the growth of KP-1 and human colon tumor Colo320DM cells orthotopically implanted in the pancreas and cecum, respectively. The efficacy of E7820 was comparable in the s.c. and orthotopic transplantation models. Immunohistochemical analyses using anti-CD31 antibody showed that E7820 significantly reduced microvessel density in orthotopically implanted KP-1 tumor. E7820 reduced integrin {alpha}2 expression on a megakaryocytic cell line, Dami cells, induced by phorbol 12-myristate 13-acetate treatment. It also decreased the expression level of integrin {alpha}2 on platelets withdrawn from mice bearing s.c. KP-1 tumor at a dosage close to that affording antitumor activity. These data demonstrate that E7820 showed a broad-spectrum antitumor effect in mice through inhibition of angiogenesis and indicate that the decrease of integrin {alpha}2 on platelets might serve as a biological marker for the antitumor efficacy of E7820.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Angiogenesis, the formation of new blood vessels, is essential for growth and malignancy of tumors (1) and an antiangiogenesis strategy is expected to provide new therapeutics to treat cancer. Angiogenesis is initiated by degradation of extracellular matrix, followed by cell migration, proliferation and capillary tube formation of endothelial cells, and then maturation. Angiogenic factors, such as vascular endothelial growth factor (VEGF; Ref. 2 ), angiopoietin (3) , and fibroblast growth factor (4) , regulate the progression of angiogenesis in cooperation with cell adhesion molecules such as integrins (5) , cadherin (6) , and platelet/endothelial cell adhesion molecule (7) . Extracellular matrix-degrading proteolytic enzymes, including matrix metalloproteinases (8) and plasminogen activator (9) , also participate in angiogenesis. Several types of inhibitors, such as VEGF inhibitors (10) , matrix metalloproteinase inhibitors (11) , and integrin antagonists (12) , have been reported to inhibit angiogenesis (13) and have already been evaluated clinically (14, 15, 16) . Among them, anti-VEGF antibody (Ab) is expected to be the new drug for cancer patients (17) .

Studies in preclinical models suggested that most angiogenesis inhibitors might cause transition of a growing tumor to a dormant state, rather than tumor regression, although some angiogenesis inhibitors have induced dramatic regression of a few well-established tumors (12 , 18) . Clinical studies also indicate that angiogenesis inhibitors might stabilize tumor growth (14 , 15) . Thus, long-term dosing may be necessary to obtain clinical benefits such as disease-free survival and increased life span. Angiogenesis inhibitors appear to have a wide therapeutic ratio, and administration at the maximum-tolerated dose may not be needed (14 , 16) . Thus, several exploratory clinical investigations to find appropriate dosages have been conducted by using magnetic resonance imaging analysis (19) , measurement of endothelial cell apoptosis (20) , and DNA microarray analysis (21 , 22) . Therefore, we thought it would be valuable to identify a surrogate marker in preclinical model study, which would be useful in predicting adequate dosage levels of angiogenesis inhibitors for clinical use.

We reported previously that E7820, an aromatic sulfonamide derivative, is a novel angiogenesis inhibitor that inhibits both proliferation and tube formation of human umbilical vein endothelial cell (HUVEC) induced by either basic fibroblast growth factor (bFGF) or VEGF (23) . E7820 decreased integrin {alpha}2, 3, 5, and ß1 in confluent cultures of HUVEC. In particular, E7820 reduced only integrin {alpha}2 mRNA as an early event. Furthermore, the suppression of integrin {alpha}2 on HUVEC by E7820 treatment contributed to the inhibition of tube formation in a type I collagen matrix culture model.

In the present study, we first examined the in vivo pharmacological efficacy of E7820 against both angiogenesis and tumor growth. In vivo antiangiogenic effects of E7820 were examined by using angiogenic factor-induced and tumor-induced angiogenesis models. We examined the antitumor effect of E7820 on growth of orthotopically implanted tumors in addition to s.c. inoculated tumors to determine the effect of E7820 on organ-specific endothelial cells. Secondly, we examined the alteration of integrin {alpha}2 expression on a megakaryocytic cell line in vitro and on platelets in a xenograft model. E7820 showed antitumor activity in various human tumor xenograft models and suppressed integrin {alpha}2 expression on platelets at a dosage similar to that inhibiting tumor growth in the xenograft models.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Lines and Cell Culture.
The tumor cell lines were purchased from the American Type Culture Collection (Rockville, MD), except for KP-1, which was obtained from National Kyusyu Cancer Center (Fukuoka, Japan); WiDr, which was obtained from Dainippon Seiyaku (Osaka, Japan); and RCC-1, which was obtained from Central Institute for Experimental Animals (Kawasaki, Japan). The tumor cells were maintained in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, penicillin (100 units/ml), streptomycin (100 µg/ml), 2-mercaptoethanol (50 µM) and sodium pyruvate (1 mM). HUVECs were isolated from human umbilical vein by the method described previously (24) , amplified in epithelial growth medium (2% FCS; Cambrex, Walkerville, MD) on type I collagen-coated flasks and used at passages 4 to 6.

Monoclonal Antibody.
Mouse monoclonal antihuman integrin {alpha}2 Ab (A2-IIE10) was purchased from Upstate Biotechnology Inc. (Lake Placid, NY). FITC-conjugated F(ab')2 fragment of rabbit antimouse IgG was purchased from Dako (Glostrup, Denmark). FITC-conjugated hamster monoclonal antimouse {alpha}2 Ab, rat monoclonal antimouse CD31 Ab (MEC13.3), FITC-conjugated rat monoclonal antimouse CD31 Ab, FITC-conjugated hamster IgG and FITC-conjugated rat IgG were purchased from PharMingen (San Diago, CA).

Preparation of E7820.
For in vitro assay, E7820 was first dissolved in DMSO and diluted further in medium. For in vivo studies, E7820 was suspended in 5% methylcellulose. In dorsal air sac (DAS) model, E7820 was dissolved in 35% DMSO and 65% Tween 80 at 100 mg/ml. The solution was diluted to final concentration with 5% glucose.

Sandwich Tube Formation Assay.
The tube formation assay was performed as described previously (23) . Briefly, HUVEC were plated on the collagen gel at a concentration of 1 to 1.2 x 105 cells/well (24-well plate) in serum-free medium (human endothelial-serum-free basal growth medium; Life Technologies, Inc., Grand Island, NY) with EGF (Life Technologies, Inc., Grand Island, NY) at 10 ng/ml and either bFGF (Life Technologies, Inc., Grand Island, NY) or VEGF (Wako Pure Chemical Industries, Osaka, Japan) at 20 ng/ml. Then, HUVEC were covered with a second collagen gel and cultured with or without E7820 in serum-free medium supplemented with angiogenic factors. Tube length of capillaries was quantified by calculating the pixel density of outline images based on images obtained with a microscope. All experiments were done at least in duplicate and were repeated three times.

Cell Growth Assay.
Cell growth assay for endothelial cells was performed as described previously (23) . Tumor cells were plated at 1 to 2 x 103 cells/well on 96-well plates in 0.1 ml of RPMI 1640 containing 10% fetal bovine serum. After 24 h, either E7820 or vehicle was added to duplicate cultures of cells, and at 2 or 3 days after addition of E7820, the ratios of surviving cells were measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. All experiments were done at least in duplicate and repeated twice.

In Vivo Growth Factor-Induced Angiogenesis.
The method described by Passaniti et al. (25) was used, with some modification. Briefly, bFGF (300 ng/pellet) was embedded in a pellet of Matrigel (300 µl; Becton Dickinson, Bedford, MA) and injected s.c. in C57BL/6N mice (Charles River Japan, Inc., Kanagawa, Japan). Vehicle or E7820 was given orally, by gavage, for 7 days (twice daily) after Matrigel implantation. At autopsy, the pellet was removed, and the hemoglobin content was measured by Drabkin’s procedure (Drabkin reagent kit; Sigma, St. Louis, MO), according to the manufacturer’s instructions.

Mouse DAS Model.
The mouse DAS method was performed as described previously (26) . Briefly, a suspension of 1.5 x 107 WiDr cells in collagen gel was injected into a chamber. This chamber was implanted into a DAS produced by injecting 10 ml of air into a C57BL/6N mouse. Administration of E7820 was started at 6 h after the transplantation (day 1). Vehicle or E7820 was given orally, by gavage, for 4 days (once daily). On day 5, 51Cr-labeled (Amersham Pharmacia Biotech, Tokyo, Japan) blood cells were injected into the tail vein of mice. Vascular volume was calculated from the radioactivity of the skin attached to the chamber.

Xenograft Model.
Six-week-old female nude mice (KSN mice; SLC, Shizuoka, Japan) underwent s.c. transplantation of human tumors (5–10 x 106 cells/mouse, except for RCC-1; 2- to 3-mm tumor fragments). Administration was started when the tumor volume reached 60–100 mm3 (except for AsPC-1; one day after transplantation). E7820 was administered orally on a schedule of twice daily every day for 3–6 weeks. Tumor volumes were checked twice a week during the experiment by direct measurement of the diameter of tumors with calipers. Tumor volume was calculated using the formula (a x b x b)/2, where a is the largest diameter and b is the diameter perpendicular to a. Values of {Delta}T/C (% of control for {Delta}growth) were calculated from the formula, ({Delta}T/{Delta}C) x 100, where {Delta}T and {Delta}C are changes in tumor volume ({Delta} growth) for each treated and vehicle control group. In the case of reduction of tumor volume, {Delta}T/C values were calculated according to the following formula, {Delta}T/C (%) = (TVn-TV1)/TV1 x 100, where TVn is the tumor volume of treated mice on day n.

Orthotopic Transplantation Model.
Seven-week-old female KSN mice were anesthetized and an incision was made at the abdomen. The tail of the pancreas or cecum was gently exposed. Seven million human pancreatic cancer cells (KP-1) were injected into the parenchyma of the pancreatic gland. A 20-mg block of human colon cancer tumor tissue (Colo320DM) was implanted on the cecum. The administration of E7820 was started 7 or 8 days (day 1) after transplantation. In the pancreatic orthotopic transplantation model, E7820 was orally administered twice daily for 21 days. On day 22, the locally grown tumors were resected, weighed, and then used for immunohistochemistry. In colon orthotopic transplantation model, E7820 was administered twice daily for 2 weeks. On day 15, the locally grown tumors were weighed and photographed.

Histological Analysis of Tumor Blood Vessels.
The resected tumors were mounted in OCT compound (Miles Scientific, Naperville, IL), frozen, and stored at -80°C until required. Frozen tumor sections were cut and stained by indirect immunoperoxidase with rat antimouse CD31 monoclonal Ab, which detects vascular endothelial cells in the tumor. Immune staining with anti-CD31 Ab was performed according to the method described previously (26) . Tumor vessels were counted by microscopy in x33 fields (2–5 fields/tumor) and were calculated as vessel density (/mm2).

Analysis by Flow Cytometry.
Dami cells, a megakaryocytic cell line, were stimulated with 2 nM phorbol 12-myristate 13-acetate (Sigma, St. Louis, MO) and cultured either with or without E7820 at the indicated doses for 72 h. The cells were harvested and suspended at 2 x 105 cells in 100 µl of PBS containing 0.1% BSA, then incubated with 1 µg of primary antibodies (antihuman integrin {alpha}2 Ab) for 30 min at 4°C. Cells were washed with PBS and incubated in FITC-conjugated secondary Ab diluted 1:40 in PBS for 30 min at 4°C. The control sample (for background) was incubated with control IgG in PBS containing 0.1% BSA. Fluorescence signals from 1 x 104 cells were acquired using a fluorescence-activated cell sorter (Calibur; Becton Dickinson, Mountain View, CA) to quantify staining intensity. The expression of each molecule was calculated using the mean fluorescence of each sample as determined by flow cytometry: Relative expression (relative mean fluorescence intensity; RMFI) = mean fluorescence intensity (MFI) of sample/MFI of background.

Evaluation of the Expression Level of Integrin {alpha}2 on Platelets in KP-1 Xenograft Model.
Six-week-old female nude mice (KSN mice) underwent s.c. transplantation of KP-1 human pancreatic tumor. Administration was started (day 1) at 7 days after transplantation. E7820 was administered orally twice daily for 3 weeks. The expression level of integrin {alpha}2 on platelets of mice treated with either vehicle or E7820 was measured once a week. Blood was withdrawn from the eye of anesthetized mice in PBS containing 0.004% sodium citrate and diluted at 1:100. Diluted blood samples were directly stained with FITC-conjugated anti-integrin {alpha}2 Ab or anti-CD31 Ab, and expression levels on platelets were analyzed by flow cytometry. Forward scatter and side scatter were used for gating of platelets. For evaluation of numbers of platelets, blood was collected from the aorta and counted with a Total Hematology Management System (Technicon H*1; Bayer Co.).


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Antiangiogenic Effect of E7820.
We first examined the effects of E7820 on proliferation of endothelial cells and tumor cells and also on tube formation of endothelial cells. Proliferation of HUVEC induced by either bFGF and VEGF in serum-free medium was inhibited by E7820 treatment and IC50 values of 0.10 and 0.081 µg/ml, respectively (Table 1)Citation . However, the in vitro antiproliferative activity of E7820 against tumor cells was approximately 100-fold less potent than that against endothelial cells (Table 1)Citation . E7820 also inhibited both bFGF- and VEGF-driven tube formation of HUVEC in this assay. The IC50 values were 0.20 and 0.24 µg/ml, respectively (Table 1)Citation .


View this table:
[in this window]
[in a new window]
  		Table 1 Antiangiogenic activities of E7820 in vitro

 
To examine the in vivo efficacy of E7820, we first evaluated the antiangiogenic activity of E7820 against in vivo angiogenesis induced by bFGF in the Matrigel plug assay. The mean hemoglobin content of bFGF-containing pellets was 21.8 ± 7.9 g/dl in vehicle-treated mice. The mean hemoglobin contents of bFGF-containing pellets in mice treated with E7820 at the doses of 6.25, 12.5, and 25 mg/kg, twice daily for 7 days, were 16.5 ± 8.2 (71%), 13.7 ± 4.7 (55%), and 10.1 ± 3.3 g/dl (35%), respectively (Fig. 1A)Citation . Thus, oral administration of E7820 inhibited angiogenesis induced by bFGF in a dose-dependent manner, and the effect was significant at 25 mg/kg (P < 0.01). Next, we evaluated the in vivo antiangiogenic efficacy of E7820 against human colorectal tumor (WiDr)-induced angiogenesis in a modified DAS model, which was reported to be dependent on VEGF secreted from tumor cells (26) . WiDr-induced angiogenesis was quantified as the vascular volume in the skin attached to those chambers. The mean vascular volume in the group of tumor-containing chambers was 2.56 ± 0.50 µl, whereas that of vehicle chambers was 1.27 ± 0.29 µl. The vascular volumes in E7820-treated groups were 2.32 ± 0.48 (100 mg/kg, once daily), 2.14 ± 0.46 (200 mg/kg), and 2.00 ± 0.35 µl (400 mg/kg). E7820 significantly inhibited WiDr tumor-induced angiogenesis at 200 (P < 0.05) and 400 mg/kg (P < 0.01; Fig. 1BCitation ).



View larger version (18K):
[in this window]
[in a new window]
  		Fig. 1. In vivo antiangiogenic activities of E7820. A, effect of E7820 on basic fibroblast growth factor (bFGF)-induced angiogenesis. Three hundred ng of bFGF were embedded in a pellet of Matrigel and implanted s.c. in mice. The angiogenic response was evaluated 7 days later as the hemoglobin content of the pellet. Vehicle and E7820 at dosages of 6.25, 12.5, and 25 mg/kg were administered orally twice daily for 7 days (n = 7 or 8). B, effect of E7820 on tumor-induced angiogenesis in the dorsal air sac model. The Millipore chamber containing collagen with or without WiDr cells was implanted into a dorsal air sac in mice. Vehicle and E7820 at a dosage of 100, 200, or 400 mg/kg were administered orally once daily for 4 days (n = 18–20). Four days after implantation of the chambers, the mice were killed, and the blood volume was determined as described in "Materials and Methods." The data represent means; bars, SD. #, P < 0.01 versus the group without growth factor or tumor by unpaired t test. *, P < 0.05 and **, P < 0.01 versus the vehicle group by Dunnett-type multiple comparison test. GF, growth factor.

 
Antitumor Effects of E7820 in s.c. and Orthotopic Xenograft Models.
We investigated the antitumor efficacy of E7820 against s.c. growth of seven human tumor cells derived from colon (WiDr, Colo320DM, LoVo), breast (BT-20), pancreas (KP-1, AsPC-1), and kidney (RCC-1) in xenograft models. E7820 was administered orally at 50, 100, and 200 mg/kg twice daily for 3–6 weeks from the initial day. Tumor growth was inhibited by E7820 treatment in a dose-dependent manner in all s.c. xenograft models we examined, and administration of E7820 even at 50 mg/kg showed significant antitumor activity against seven tumors (AsPC-1 by P < 0.05, others by P < 0.01; Table 2Citation ). E7820 completely inhibited s.c. tumor growth of LoVo tumor cells and also regressed the tumor mass of KP-1 tumor cells at the dosages of both 100 and 200 mg/kg (Fig. 2, A and B)Citation . E7820 treatment was well tolerated in all experiments and did not change the body weight of mice compared with vehicle-treated mice (data not shown).


View this table:
[in this window]
[in a new window]
  		Table 2 Antitumor effects of E7820 on s.c. tumor growth

 


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 2. Effects of E7820 on the growth of s.c. tumor in a xenograft model. A, response of KP-1 tumors in mice treated with E7820. Vehicle and E7820 were administered by gavage twice daily for 21 days from 7 days after inoculation of the tumor cells (n = 5). B, growth inhibition of LoVo tumors by E7820 treatment. Administration of E7820 was started by gavage twice daily when the tumor volume reached 100 mm3 and continued for 42 days (n = 6). The data represent means; bars, SD.

 
Subsequently, the antitumor effects of E7820 on the local growth of either orthotopically implanted pancreatic tumor or colon tumor at the pancreas and cecum, respectively, was evaluated. Human pancreatic tumor cells, KP-1 cells, were inoculated into the pancreas, and E7820 was administered orally at 50, 100, and 200 mg/kg from 7 days after implantation (day 1, tumor weight = 54 ± 4 mg), twice daily for 3 weeks. At autopsy, the mean tumor weight of vehicle-treated mice was 406 ± 116 mg, whereas the corresponding values for the E7820-treated groups were 217 ± 64, 80 ± 16, and 41 ± 4 mg, respectively. E7820 significantly inhibited tumor growth in the pancreas at all of the dosages examined, and the tumor weight of mice treated at 200 mg/kg was comparable with that on day 1 (Fig. 3A)Citation . Immunohistochemical analysis of KP-1 tumors by staining endothelial cells with anti-CD31 Ab showed fewer stained endothelial cells and reduced microvessel density in a cross-section of tumor from mice treated with E7820 compared with the vehicle control (Fig. 3, C-E)Citation , demonstrating antiangiogenic efficacy of E7820 against endothelial cells in the pancreas. Pieces of human colon Colo320DM tumor tissue were implanted onto the cecum, and E7820 was administered orally at 50, 100, and 200 mg/kg from 8 days after implantation (day 1), twice daily for 2 weeks. The mean tumor weight of mice treated with vehicle was 762 ± 605 mg, whereas the corresponding values in the E7820-treated groups were 285 ± 100, 254 ± 90, and 132 ± 113 mg, respectively. Thus, E7820 inhibited tumor growth significantly at the cecum at the all dosages examined (Fig. 3B)Citation . Furthermore, Colo320DM tumors growing on the cecum were reddish in vehicle-treated mice, whereas those in E7820-treated mice were pale in color (Fig. 3F)Citation .



View larger version (65K):
[in this window]
[in a new window]
  		Fig. 3. Effect of E7820 on local growth of orthotopically transplanted tumor. A, antitumor effect against human pancreatic KP-1 tumor inoculated into the pancreas. The administration of E7820 was started 7 days (day 1) after transplantation. E7820 was orally administered twice daily for 21 days. On day 1 and day 22, the locally growing tumor was resected and weighed. The vehicle control group and E7820-treated group consisted of 10 and 8 mice, respectively. B and F, antitumor effect against human colorectal Colo320DM tumor implanted on the cecum. Vehicle and E7820 were administered by gavage twice daily for 14 days from 8 days after implantation. F, on day 15, the locally growing tumor was weighed and photographed. The vehicle control group consisted of 12 animals. The E7820-treated group consisted of seven or eight mice. C and D, immunohistochemical analysis of intratumoral blood vessels in the KP-1 orthotopic transplantation model. The KP-1 tumors growing at the pancreas from mice treated with either 200 mg/kg E7820 or vehicle were excised, embedded in OCT compound (Miles Scientific), frozen and stained with a rat antimouse CD31 primary antibody. Brown staining indicates endothelium. C, vehicle. D, E7820 at 200 mg/kg. E, measurement of vessel density (/mm2). The data represent means; bars, ±SD. **, P < 0.01 versus the vehicle group by Dunnett-type multiple comparison test.

 
Effect of E7820 on Expression Level of Integrin {alpha}2 on Platelet.
Flow cytometric analysis showed that the expression level of integrin {alpha}2 on Dami cells was up-regulated by phorbol 12-myristate 13-acetate treatment for 3 days. This up-regulation of integrin {alpha}2 was inhibited in the presence of E7820 in a dose-dependent manner. Relative mean fluorescence intensity of integrin {alpha}2 on Dami cells without E7820 treatment was 30.8 ± 4.8, whereas the corresponding values for cells treated with E7820 at 5, 50, and 500 ng/ml were 19.6 ± 10.2, 13.0 ± 2.5, and 6.7 ± 2.3, respectively (Fig. 4)Citation . To investigate whether the expression level of integrin {alpha}2 on platelets is altered by E7820 treatment in vivo, we measured sequentially the expression level of integrin {alpha}2 on platelets from mice treated with E7820 in the KP-1 xenograft model, accompanied with measurement of the tumor volumes. E7820 was administered twice daily for 3 weeks orally from 7 days after transplantation. E7820 induced a dose-dependent reduction of integrin {alpha}2 expression on platelets (Fig. 5B)Citation . These effects of E7820 were detected from 7 days after initial administration and were significant at all dosages examined on day 22. The integrin {alpha}2 expression on platelets in E7820-treated mice was restored after withdrawal of E7820 treatment for 7 days, whereas the antitumor activity remained at 100 and 200 mg/kg (Fig. 5, A and B)Citation . The expression level of CD31 was less affected by E7820 treatment (Fig. 5C)Citation . Decrease of CD31 expression on platelets was observed only at the highest dose (200 mg/kg). Decrease of {alpha}2 integrin expression on platelets was detected at doses close to those showing antitumor activity. The number of platelets was not changed by administration of E7820 for 3 weeks (data not shown).



View larger version (20K):
[in this window]
[in a new window]
  		Fig. 4. Effect of E7820 on expression of integrin {alpha}2 on human megakaryocytic cell line. Flow cytometric analysis of the expression level of integrin {alpha}2 on Dami cells stimulated with phorbol 12-myristate 13-acetate (PMA; 2 nM) for 72 h (n = 3). The data represent means; bars, SD. #, P < 0.01 versus the group without PMA by unpaired t test. *, P < 0.05 and **, P < 0.01 versus the vehicle group by Dunnett-type multiple comparison test.

 


View larger version (18K):
[in this window]
[in a new window]
  		Fig. 5. Effect of E7820 on expression level of integrin {alpha}2 on platelets in the KP-1 xenograft model. A, antitumor effect of E7820. Vehicle and E7820 at a dosage of 25, 50, 100, or 200 mg/kg were administered by gavage twice daily (b.i.d.) for 21 days from 7 days (day 1) after s.c. inoculation of KP-1 cells, and the tumor volume was measured on day 36. B, expression of integrin {alpha}2 on platelets of mice treated with either E7820 or vehicle. C, expression of CD31 on platelets of mice treated with either E7820 or vehicle. For evaluation of the expression levels of integrin {alpha}2 and CD31 on platelets, blood was withdrawn from eye of anesthetized mice into PBS containing 0.3% sodium citrate and diluted at 1:100. Diluted blood samples were directly stained by FITC-conjugated each antibody, and expression levels were analyzed by flow cytometry in platelet. {blacksquare}, vehicle; x, 25 mg/kg; {square}, 50 mg/kg; {triangleup}, 100 mg/kg; {circ}, 200 mg/kg. Each group consisted of five mice and data represent means; bars, SD. **, P < 0.01 versus the vehicle group by Dunnett-type multiple comparison test. RMFI, relative mean fluorescence intensity.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
We reported previously that E7820, an aromatic sulfonamide derivative, showed antiangiogenic activity through inhibition of proliferation and tube formation of endothelial cells (23) . Additionally, we confirmed that E7820 inhibited tube formation through suppression of integrin {alpha}2. In the present report, the in vivo pharmacological profile of E7820 was examined. Furthermore, we suggested that alteration of integrin {alpha}2 expression on platelets might serve as a biological marker for efficacy of E7820.

E7820 inhibited both bFGF-induced angiogenesis in a Matrigel plug model and tumor (human colorectal WiDr tumor cell)-induced vascularization in the DAS model after oral administration. In addition, we reported previously that angiogenesis induced by WiDr cells was dependent on VEGF in the DAS model (26) , suggesting that E7820 is effective against both bFGF- and VEGF-dependent angiogenesis in vivo as well as in vitro. E7820 showed broad-spectrum tumor inhibition at doses from 50 to 200 mg/kg in s.c. xenograft models involving human colon, breast, pancreas, and kidney tumor. It might be important to inhibit multiple factors for effective inhibition of tumor angiogenesis, because it was reported that multiple angiogenic factors are secreted from tumor cells, and expression of angiogenic factors was increased in late-stage tumors (27) . The in vitro growth of tumor cells we examined was extremely insensitive to E7820 compared with that of HUVEC, as shown in Table 1Citation , except for RCC-1 (in vivo passaging tumor line). The microvessel density in tumor tissue was also reduced after E7820 treatment. These results suggested E7820 inhibits tumor growth through angiogenesis inhibition in mice. E7820 was well tolerated in all of the in vivo experiments. Its profile was consistent with that of an angiogenesis inhibitor.

Blood vessels in different organs are known to be functionally and structurally different from each other. Furthermore, it was reported that angiogenic heterogeneity was regulated by the organ microenvironment of the tumor. Histopathological analysis in a human renal carcinoma xenograft model showed that tumors growing in the subcutis of mice had few blood vessels compared with those in the kidney, which had many vessels (28) . In a human colon carcinoma xenograft model, angiogenic factors such as bFGF and interleukin-8 in tumor tissues were increased in the cecal wall region as compared with s.c. tissue (29) . These findings prompted us to consider the possibility that the activity of angiogenesis inhibitors might vary in different organ-specific endothelial cells. The effect of E7820 on organ-specific endothelial cells was examined in orthotopically inoculated KP-1 pancreatic and Colo320DM colon cancer cells. E7820 had a similar antitumor effect against both local growth at orthotopic sites and s.c. growth of KP-1 and Colo320DM tumors (Table 2Citation ; Fig. 3Citation ). These results suggested that E7820 was able to affect endothelial cells of skin, pancreas, and colon. E7820 also showed an antitumor effect against tumor growth at the mammary fat pad (data not shown) and seems to be effective on endothelial cells specific for various organs.

The results of recent clinical studies suggested that angiogenesis inhibitors have modest toxicity and induce stabilization of disease (14 , 15) . The induction of tumor dormancy is considered to be a clinically useful outcome that might increase disease-free survival and survival time. Compared with standard evaluation in terms of response rate, long-term dosing may be required for evaluation of this type of drug. Therefore, a surrogate marker other than response rate is needed to allow evaluation of the biological effects of angiogenesis inhibitors in early phase studies of short duration and to identify appropriate dosages, which are not close to the maximum-tolerated dose but are sufficient to show antiangiogenic activity. Because the inhibitory effect of E7820 on tube formation of HUVEC within type I collagen gels resulted from a decrement of integrin {alpha}2 expression (23) , we examined whether this unique biological profile could be applied as a marker for the biological effect of E7820. Integrin {alpha}2 was reported to be a collagen receptor on platelets and to be involved in platelet aggregation (30) . Platelets are derived from megakaryocytes, and integrin {alpha}2 is up-regulated in the process of megakaryocyte differentiation toward platelets (31) . In an in vitro model of megakaryocyte differentiation using human megakaryocytic Dami cells (32) , E7820 suppressed phorbol 12-myristate 13-acetate-induced expression of integrin {alpha}2 at a similar concentration to that at which it was effective on HUVEC (Fig. 4)Citation . Furthermore, oral administration of E7820 decreased integrin {alpha}2 expression on platelets during treatment in the KP-1 s.c. xenograft model. The effective dose for decreasing integrin {alpha}2 expression on platelets was comparable with that for inhibiting s.c. growth of KP-1 tumor cells. Because the number of platelets was not changed in mice treated with E7820, E7820 might suppress integrin {alpha}2 expression in megakaryocytes without affecting platelet differentiation. It was unclear whether the mechanism by which expression of integrin {alpha}2 subunits is regulated in endothelial cells is the same as that in megakaryocytes. However, the comparable effects of E7820 on integrin {alpha}2 expression on platelets and growth of KP-1 tumor cells suggested that the decrement of integrin {alpha}2 expression on platelets might be useful as a marker for biological effect of E7820. Expression levels of integrin {alpha}2 on platelets of individual humans differ. However, in each healthy volunteer examined, the level of integrin {alpha}2 expression on platelets was constant over 2 weeks [RFMI ratio to day 1: 0.94 ± 0.01 (Day 8), 1.01 ± 0.02 (day 15), n = 3]. Therefore, integrin {alpha}2 on platelets could be used as a biological marker by monitoring its expression level before and after E7820 treatment in clinical studies.

E7820 was highly effective against s.c. growth of LoVo and KP-1 cells among the in vivo tumor panel. Moreover, E7820 regressed the tumor mass of KP-1 tumor cells in the s.c. xenograft model. Some angiogenesis inhibitors, such as VEGF receptor kinase inhibitor, an integrin antagonist (12 , 18) , have been shown to promote tumor regression by inducing apoptosis of tumor vasculature. It is possible that E7820 might induce apoptosis of endothelial cells in KP-1 tumor. Because it was reported that the survival of endothelial cells was dependent on a survival signal via integrin (12) , the difference of integrin expression on vascular endothelial cells of tumor tissues might be involved. Integrin {alpha}vß3 was reported to have a critical role in tumor angiogenesis. Expression of both {alpha}1ß1 and {alpha}2ß1 was reported to be induced by VEGF, and an inhibitory Ab against {alpha}1ß1 and {alpha}2ß1 inhibited not only angiogenesis by VEGF-overexpressing tumor cells but also tumor growth in mice (33 , 34) . Therefore, it is of interest to examine integrin expression on intratumoral endothelial cells in KP-1 tumor.

E7820 is a novel angiogenesis inhibitor that has a unique biological activity suppressing an expression of integrin {alpha}2 subunit. Although many angiogenesis inhibitors are now being clinically evaluated, combination therapy with angiogenesis inhibitors that act on different processes of angiogenesis might be a worthwhile approach to potentiate the antitumor effect. In summary, we have shown in this study that E7820 has promising antitumor effects in a preclinical model through inhibition of angiogenesis and that monitoring the expression level of integrin {alpha}2 on platelets might be a valuable predictive marker for the biological effect of E7820. A clinical evaluation of E7820 seems warranted.


   ACKNOWLEDGMENTS
 
We thank Dr. Funakoshi (National Kyusyu Cancer Center, Fukuoka, Japan) for providing KP-1 human pancreatic cancer cell line. The technology of surgical orthotopic implantation is licensed from AntiCancer Inc. (San Diego, CA).


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Taro Semba, Tsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki, Japan. Phone: 81-29-847-5749; Fax: 81-29-847-2037; E-mail: t-semba{at}hhc.eisai.co.jp

Received 8/28/03; revised 11/10/03; accepted 11/12/03.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.[CrossRef][Medline]
  2. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med., 77: 527-543, 1999.[CrossRef][Medline]
  3. Suri C., McClain J., Thurston G., McDonald D. M., Zhou H., Oldmixon E. H., Sato T. N., Yancopoulos G. D. Increased vascularization in mice overexpressing angiopoietin-1. Science (Wash. DC), 282: 468-471, 1998.[Abstract/Free Full Text]
  4. Klagsbrun M., D’Amore P. A. Regulators of angiogenesis. Ann. Rev. Physiol., 53: 217-239, 1991.[CrossRef][Medline]
  5. Eliceiri B. P., Cheresh D. A. Adhesion events in angiogenesis. Curr. Opin. Cell Biol., 5: 563-568, 2001.
  6. Bach T. L., Barsigian C., Chalupowicz D. G., Busler D., Yaen C. H., Grant D. S., Martinez J. VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. Exp. Cell Res., 238: 324-334, 1998.[CrossRef][Medline]
  7. DeLisser H. M., Christofidou-Solomidou M., Strieter R. M., Burdick M. D., Robinson C. S., Wexler R. S., Kerr J. S., Garlanda C., Merwin J. R., Madri J. A., Albelda S. M. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am. J. Pathol., 151: 671-677, 1997.[Abstract]
  8. Uemori E. N., Ferrara N., Bauer E. A., Amento E. P. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J. Cell. Physiol., 153: 557-562, 1992.[CrossRef][Medline]
  9. Pepper M. S., Ferrara N., Ocri L., Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun., 181: 902-906, 1991.[CrossRef][Medline]
  10. Fong T. A., Shawver L. K., Sun L., Tang C., App H., Powell T. J., Kim Y. H., Schreck R., Wang X., Risau W., Ullrich A., Hirth K. P., McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 59: 99-106, 1999.[Abstract/Free Full Text]
  11. Wojtowicz-Praga S. M., Dickson R. B., Hawkins M. J. Matrix metalloproteinase inhibitors. Investig. New Drugs, 15: 61-75, 1997.[CrossRef][Medline]
  12. Brooks P. C., Montgomery A. M., Rosenfeld M., Reisfeld R. A., Hu T., Klier G., Cheresh D. A. Integrin {alpha}vß3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79: 1157-1164, 1994.[CrossRef][Medline]
  13. Madhusudan S., Harris A. L. Drug inhibition of angiogenesis. Curr. Opin. Pharmacol., 2: 403-414, 2002.[CrossRef][Medline]
  14. Scappaticci F. A. Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol., 20: 3906-3927, 2002.[Abstract/Free Full Text]
  15. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer, 2: 727-739, 2002.[CrossRef][Medline]
  16. Cristofanilli M., Charnsangavej C., Hortobagyi G. N. Angiogenesis modulation in cancer research: novel clinical approaches. Nat. Rev. Drug Discov., 1: 415-426, 2002.[CrossRef][Medline]
  17. Kabbinavar F., Hurwitz H. I., Fehrenbacher L., Meropol N. J., Novotny W. F., Lieberman G., Griffing S., Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol., 21: 60-65, 2003.[Abstract/Free Full Text]
  18. Laird A. D., Christensen J. G., Li G., Carver J., Smith K., Xin X., Moss K. G., Louie S. G., Mendel D. B., Cherrington J. M. SU6668 inhibits Flk-1/KDR and PDGFRß in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J., 16: 681-690, 2002.[Abstract/Free Full Text]
  19. Pham C. D., Roberts T. P., van Bruggen N., Melnyk O., Mann J., Ferrara N., Cohen R. L., Brasch R. C. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Investig., 16: 225-230, 1998.[Medline]
  20. Shaheen R. M., Davis D. W., Liu W., Zebrowski B. K., Wilson M. R., Bucana C. D., McConkey D. J., McMahon G., Ellis L. M. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res., 59: 5412-5416, 1999.[Abstract/Free Full Text]
  21. Zogakis T. G., Costouros N. G., Kruger E. A., Forbes S., He M., Qian M., Feldman A. L., Figg W. D., Alexander H. R., Liu E. T., Kohn E. C., Libutti S. K. Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay. Biotechniques, 33: 664-666, 668, 670, 2002.[Medline]
  22. Costouros N. G., Libutti S. K. Microarray technology and gene expression analysis for the study of angiogenesis. Expert. Opin. Biol. Ther., 2: 545-556, 2002.[Medline]
  23. Funahashi Y., Sugi N. H., Semba T., Yamamoto Y., Hamaoka S., Tamai N. T., Ozawa Y., Tsuruoka K., Nara K., Takahashi K., Okabe T., Kamata J., Owa T., Ueda N., Haneda T., Yonaga M., Yoshimatsu K., Wakabayashi T. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin {alpha}2 subunit on endothelium. Cancer Res., 62: 6116-6123, 2002.[Abstract/Free Full Text]
  24. Jaffe E. A., Nachman R. L., Becker C. G., Minick C. R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Investig., 52: 2745-2756, 1973.
  25. Passaniti A., Taylor R. M., Pili R., Guo Y., Long P. V., Haney J. A., Pauly R. R., Grant D. S., Martin G. R. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Investig., 67: 519-528, 1992.[Medline]
  26. Funahashi Y., Wakabayashi T., Semba T., Sonoda J., Kitoh K., Yoshimatsu K. Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor. Oncol. Res., 11: 319-329, 1999.[Medline]
  27. Relf M., LeJeune S., Scott P. A., Fox S., Smith K., Leek R., Moghaddam A., Whitehouse R., Bicknell R., Harris A. L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res., 57: 963-969, 1997.[Abstract/Free Full Text]
  28. Fidler I. J. Angiogenic heterogeneity: Regulation of neoplastic angiogenesis by the organ microenvironment. J. Natl. Cancer Inst. (Bethesda), 93: 1040-1041, 2001.[Free Full Text]
  29. Kitadai Y., Bucana C. D., Ellis L. M., Anzai H., Tahara E., Fidler I. J. In situ mRNA hybridization technique for analysis of metastasis-related genes in human colon carcinoma cells. Am. J. Pathol., 147: 1238-1247, 1995.[Abstract]
  30. Nieuwenhuis H. K., Akkerman J. W., Houdijk W. P., Sixma J. J. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature (Lond.), 318: 470-472, 1985.[CrossRef][Medline]
  31. Zutter M. M., Painter A. A., Staatz W. D., Tsung Y. L. Regulation of {alpha}2 integrin gene expression in cells with megakaryocytic features: a common theme of three necessary elements. Blood, 86: 3006-3014, 1995.[Abstract/Free Full Text]
  32. Baatout S., Chatelain B., Staquet P., Symann M., Chatelain C. Protein content and number of nucleolar organizer regions are enhanced during phorbol ester-induced differentiation of cultured human megakaryocytic cells. Anticancer Res., 19: 3229-3235, 1999.[Medline]
  33. Senger D. R., Claffey K. P., Benes J. E., Perruzzi C. A., Sergiou A. P., Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through {alpha}1ß1 and {alpha}2ß1 integrins. Proc. Natl. Acad. Sci. USA, 94: 13612-13617, 1997.[Abstract/Free Full Text]
  34. Senger D. R., Perruzzi C. A., Streit M., Koteliansky V. E., de Fougerolles A. R., Detmar M. The {alpha}1ß1 and {alpha}2ß1 integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am. J. Pathol., 160: 195-204, 2002.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. L. Figueiredo, Y. Kim, M. A.R. St. John, and D. T.W. Wong
p12CDK2-AP1 Gene Therapy Strategy Inhibits Tumor Growth in an In vivo Mouse Model of Head and Neck Cancer
Clin. Cancer Res., May 15, 2005; 11(10): 3939 - 3948.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Semba, T.
Right arrow Articles by Wakabayashi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Semba, T.
Right arrow Articles by Wakabayashi, T.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online